Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs
MSFT -7.97META 2.815BKNG 0.45HMP.TO 0SPGP 0.19ZUQ.TO -0.34NVDA -3.89GL 0.93
Dimethaid (DMX.TO)
The ultimate 360° Tracker Your financial life in one place, automatically

Dimethaid (DMX.TO)

0.00
-0.00 (0.00%)
115 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
DON'T BUY

Dimethaid(DMX.TO)

Sep 15, 2005
New management. Doesn't follow this company actively because it doesn't have much in the way of earnings. In the bottom 10% of his database.
Photo of Robert McWhirterRobert McWhirter
No
Unlock Rating
$0.19

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Dimethaid(DMX.TO)

Jan 25, 2005
Very much news driven. Speculative. Need a very strong stomach.
Photo of David BaskinDavid Baskin
No
Unlock Rating
$0.40

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Dimethaid(DMX.TO)

Nov 27, 2003
Looked like it was going to break out of a 200-day moving average but fell back. Did a special warrant financing in October for sales/marketing of Pennsaid. FDA approval has been pending for a long time. Caution.
Photo of Lou SchizasLou SchizasUnlock Rating
$1.33

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Dimethaid(DMX.TO)

Jul 03, 2003
Has been losing value for some time. Need to have a lot of faith. They are still waiting for a green light from the FDA. The big risk is their inability to move sales.
Photo of Lou SchizasLou SchizasUnlock Rating
$1.74

Stock price when the opinion was issued

biotechnologypharmaceutical
BUY

Dimethaid(DMX.TO)

Mar 27, 2003
A this point, its a reasonable bet.
Photo of Robert FloydRobert FloydUnlock Rating
$2.09

Stock price when the opinion was issued

biotechnologypharmaceutical
BUY

Dimethaid(DMX.TO)

Mar 19, 2001
Approaching commercialization.
Photo of Ed HoEd HoUnlock Rating
$7.25

Stock price when the opinion was issued

biotechnologypharmaceutical
WATCH

Dimethaid(DMX.TO)

Jan 02, 2001
Attractive, but wait for partnership deal with Johnson & Johnson
Photo of Steven MisenerSteven MisenerUnlock Rating
$8.10

Stock price when the opinion was issued

biotechnologypharmaceutical
BUY

Dimethaid(DMX.TO)

Nov 29, 2000
Not a big enough following but should be OK
Photo of Pier DonniniPier DonniniUnlock Rating
$5.60

Stock price when the opinion was issued

biotechnologypharmaceutical
BUY

Dimethaid(DMX.TO)

Oct 13, 2000
Good techs. Have to convince the Feds its a good way to deliver pain relief
Photo of Glenn Paradis, BA, CFAGlenn Paradis, BA, CFAUnlock Rating
$5.00

Stock price when the opinion was issued

biotechnologypharmaceutical
Showing 1 to 9 of 9 entries
  • «
  • ‹
  • 1
  • ›
  • »

Dimethaid (DMX.TO) Frequently Asked Questions

What is Dimethaid stock symbol?

Dimethaid is a OTC stock, trading under the symbol DMX.TO (previously DMX-T on Stockchase) on the undefined (undefined). It is usually referred to as or DMX.TO

Is Dimethaid a buy or a sell?

In the last year, no analyst issued a Buy, Sell, or Hold rating on DMX.TO (previously DMX-T on Stockchase) on Stockchase. Read the latest expert commentary for Dimethaid.

Is Dimethaid a good investment or a top pick?

Dimethaid was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Dimethaid.

Why is Dimethaid stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Dimethaid.

Is Dimethaid worth watching?

Dimethaid is followed by 115 investors on Stockchase and is a trending stock that is worth watching.

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

FCX -0.2$69.93
MU -41.09$1046.9
WDC 45.93$699.46
AAPL 2.53$298.95
SPCX 23.15$215.65

Today's Top Picks

MSFT -7.97$391.79
META 2.815$596.295
BKNG 0.45$175.09
HMP.TO 0$9.76
SPGP 0.19$121.79

Popular Articles

Latest Sell Signals

CRWD -11.56$681.35
MSFT -7.97$391.79
SCCO -0.2$193.02
ADBE 1.82$208.18
PEP 0.195$146.445

Most Recent Experts

Joe Terranova

Joe Terranova

Virtus Investment Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Rob Sechan, Managing Partner, New Edge Capital

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Gordon Reid

Gordon Reid

GoodReid Investment Counsel

Jim Cramer - Mad Money

Jim Cramer - Mad Money

CNBC

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica